Karo Pharma AB completes voluntary offer for Weifa ASA
(Thomson Reuters ONE) -
Karo Pharma AB ("Karo Pharma") has today successfully completed the voluntary
offer for Weifa ASA ("Weifa"). Payment of the offer price is being made today to
the Weifa shareholders who accepted the voluntary offer and the cash
consideration will be available on such shareholders' registered bank accounts
in the VPS on or around 9 October 2017. At the same time, 35,453,352 tendered
shares are being transferred to Karo Pharma. As a result Karo Pharma now holds
97.21% of the shares and voting rights in Weifa.
Karo Pharma intends to effect a compulsory acquisition of the remaining shares
in Weifa at a price equal to the offer price of NOK 35 per share as soon as
possible. A separate announcement will be released once the compulsory
acquisition has been resolved in accordance with the Norwegian Securities
Trading Act section 6-22 cf. the Norwegian Public Limited Companies Act Section
4-25.
For further information, please contact:
Peter Blom, CEO of Karo Pharma, +46 070-655 56 98 or peter.blom(at)karopharma.se
Simen Nyberg-Hansen, CFO of Weifa: +47 9820 6355, or simen.nyberg-
hansen(at)weifa.no
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2017 - 14:30 Uhr
Sprache: Deutsch
News-ID 562743
Anzahl Zeichen: 1693
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karo Pharma AB completes voluntary offer for Weifa ASA"
steht unter der journalistisch-redaktionellen Verantwortung von
Weifa ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
